# MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
Canonical URL: https://biopharmsignal.com/news/MNKD/mannkind-enters-data-rich-development-period-with-completion-of-randomization-in-phase-1b-inflo-1-study-and-enrollment-of-first-patient-in-phase-2-inflo-2-trial-for-nintedanib-dpi-in-patients-with-ipf
Ticker: MNKD
Company: MannKind
Source: MannKind
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.mannkindcorp.com
## Summary

Phase 1b INFLO-1 study data readout anticipated in Q3 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today

## Article Body
Phase 1b INFLO-1 study data readout anticipated in Q3 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today
## Recent Company News
- 2026-06-25 13:46 EST — [MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D](https://biopharmsignal.com/news/MNKD/mannkind-awarded-breakthrough-t1d-grant-to-support-advancement-of-inhale-1st-pediatric-trial-of-afrezzar-in-youth-with-newly-diagnosed-t1d) — Source: MannKind
- 2026-06-25 13:46 EST — [Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems](https://biopharmsignal.com/news/MNKD/data-at-ada-2026-highlights-key-findings-from-clinical-and-real-world-studies-of-mannkind-s-afrezzar-inhaled-insulin-across-pediatric-care-pregnancy-and-use-with-automated-insulin-delivery-aid-systems) — Source: MannKind
- 2026-06-25 13:46 EST — [MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF](https://biopharmsignal.com/news/MNKD/mannkind-enters-data-rich-development-period-with-completion-of-randomization-in-phase-1b-inflo-1-study-and-enrollment-of-first-patient-in-phase-2-inflo-2-trial-for-nintedanib-dpi-in-patients-with-ipf) — Source: MannKind
- 2026-06-25 13:46 EST — [MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval](https://biopharmsignal.com/news/MNKD/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval) — Source: MannKind
- 2026-06-25 13:46 EST — [MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes](https://biopharmsignal.com/news/MNKD/mannkind-announces-fda-approval-of-afrezzar-the-first-and-only-inhaled-mealtime-insulin-for-use-in-children-and-adolescents-aged-6-and-older-living-with-diabetes) — Source: MannKind
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)